Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN
8629cov_opencxd_opt.jpg

July 21, 2008 Cover

Volume 86, Issue 29

More and more companies are using fragment-based lead design as a drug discovery strategy

Credit:

Full Article
Volume 86 | Issue 29

All Issues

Pharmaceuticals

Piece By Piece

More and more companies are using fragment-based lead design as a drug discovery strategy

  • From Diseases To Devices

    Amyloid fibrils are hallmarks of disease but also may provide a basis for advanced nanomaterials

  • A Technology Bet

    DSM's pharma products unit leverages its biotech strength to survive in a tough environment

  • NIST Plays For High Stakes

    New program for high-risk research is poised to award first grants, but future funding is unclear

ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT